Disease Specific Programmes™

Real-world Insights and Evidence

Disease Specific Programmes™ (DSPs) are Adelphi Real World’s proprietary, real-world evidence (RWE) generation programmes. Showcasing Adelphi’s leadership and heritage in RWE since 1995, Disease Specific Programmes have generated data across over 80 individual disease areas.

An objective and impartial data source, each Disease Specific Programme provides input into multiple perspectives; data have fed into brand strategies, numerous publications and reimbursement submissions, and have shaped treatment guidelines.

Disease Specific Programmes offer a view of the entire patient journey and treatment landscape from the perspective of multiple stakeholders.  Our published, citable and validated methodology ensures credible evidence generation and analysis; consistent application of the methodology across geographies allows for true cross-country comparison and analysis of trends over time.

  • Autoimmune
    Alopecia ● Atopic Dermatitis (Adult & Paediatric) ● Biosimiliars ● IBD/CD/UC ● Impetigo & Secondarily Infected Traumatic Lesions ● Lupus ● Psoriasis ● Rheumatoid Arthritis ● Spondyloarthropathy (Non-radiographic axial spondyloarthritis, Psoriatic Arthritis, Ankylosing spondylitis) ● Sjögren's Syndrome ● Urticaria/CIU
  • Cardiovascular
    Acute Coronary Syndrome ● Atrial Fibrillation ● Dyslipidaemia ● Heart Failure
  • CNS
    ADHD ● Bipolar ● Dementia ● Depression & Anxiety ● Multiple Sclerosis ● Parkinson's Disease ● Schizophrenia ● Stroke
  • Metabolic
    Chronic Kidney Disease ● Diabetes (T1DM/T2DM) ● Diabetes Devices ● Nonalcoholic Steatohepatitis ● Obesity
  • Oncology
    Haematological Tumours: Acute Myeloid Leukaemia ● Diffuse Large B-Cell Lymphoma ● Follicular Lymphoma ● Chronic Lymphocytic Leukaemia ● Multiple Myeloma ● Solid Tumours: Adjuvant Breast Cancer ● Advanced Breast cancer ● Advanced Gastric Cancer ● Glioblastoma Multiforme ● Head & Neck cancer ● Hepatocellular carcinoma ● Melanoma ● Non-small cell lung cancer ● Ovarian Cancer ● Prostate Cancer ● Renal Cell Carcinoma
  • Pain
    Cluster Headache ● Migraine ● Neuropathic Pain ● Osteoarthritis ● Osteoporosis ● Peripheral Diabetic Neuropathic Pain
  • Rare & Orphan Diseases
    Haemophilia ● Huntington's Disease ● Polycythemia vera ● Fabry Disease ● Myasthenia Gravis ● Immune thrombocytopenic purpura ● CIDP ● GvHD ● ALS
  • Respiratory
    Allergic Rhinitis ● Asthma/COPD ● Idiopathic Pulmonary Fibrosis ● Pulmonary Arterial Hypertension ● Nasal Polyps ● Severe Asthma
  • Other Conditions
    Endometriosis ● Gout ● Hepatitis-C ● Human Immunodeficiency Virus ● Hypothyroidism ● Lower Urinary Tract Symptoms ● Overactive Bladder ● Sarcopenia ● Vasomotor Symptoms

Coronavirus (COVID-19)

As we deal with the current COVID-19 pandemic, we would like to assure you that Adelphi Group are taking every step to ensure the safety and wellbeing of all our staff, families, friends and communities. All staff worldwide are working from home and following individual Government Stay at Home guidelines to do all we can to Protect the Health Services and Save Lives. (UK : https://www.gov.uk/coronavirus) We will continue to exercise ‘Business as Usual’ to ensure our work for all continues. Indeed at the beginning of this month we held an extremely successful all work from home day to test our systems and ability to continue to communicate and deliver for whatever may happen in our world. Little did we know at the time how timely this was to be, and this will be an annual business continuity measure going forward. We would also like to share with you a programme ‘I AM PATIENT‘ produced by one of our Associate Companies, Snow, emphasising the importance of pro-actively following these critically important guidelines and to take personal responsibility to help stop the spread of this deadly virus https://www.youtube.com/watch?v=jZs-F2620CI #iampatient, #stayhome Stay Safe